The Role of TNF-α in Alzheimer's Disease: A Narrative Review

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Jan 11

PMID 38201258

Authors

Domenico Plantone

Matteo Pardini

Delia Righi

Carlo Manco

Barbara Maria Colombo

Nicola De Stefano

Affiliations

Soon will be listed here.

Abstract

This review analyzes the role of TNF-α and its increase in biological fluids in mild cognitive impairment, and Alzheimer's disease (AD). The potential inhibition of TNF-α with pharmacological strategies paves the way for preventing AD and improving cognitive function in people at risk for dementia. We conducted a narrative review to characterize the evidence in relation to the involvement of TNF-α in AD and its possible therapeutic inhibition. Several studies report that patients with RA and systemic inflammatory diseases treated with TNF-α blocking agents reduce the probability of emerging dementia compared with the general population. Animal model studies also showed interesting results and are discussed. An increasing amount of basic scientific data and clinical studies underscore the importance of inflammatory processes and subsequent glial activation in the pathogenesis of AD. TNF-α targeted therapy is a biologically plausible approach for cognition preservation and further trials are necessary to investigate the potential benefits of therapy in populations at risk of developing AD.

Citing Articles

Mouse-to-human modeling of microglia single-nuclei transcriptomics identifies immune signaling pathways and potential therapeutic candidates associated with Alzheimer's disease.

Bergendorf A, Park J, Ball B, Brubaker D bioRxiv. 2025; .

PMID: 39975195 PMC: 11839086. DOI: 10.1101/2025.02.07.637100.

Osteopontin in Alzheimer's Disease: A Double-Edged Sword in Neurodegeneration and Neuroprotection-A Systematic Review.

Azizan Z, Bazrgar M, Bazgir N, Moini S, Ghaseminejad-Kermani S, Safa K CNS Neurosci Ther. 2025; 31(2):e70269.

PMID: 39957678 PMC: 11831194. DOI: 10.1111/cns.70269.

Brain interleukins and Alzheimer's disease.

Abdelhamed H, Hassan A, Sakraan A, Al-Deeb R, Mousa D, Aboul Ezz H Metab Brain Dis. 2025; 40(2):116.

PMID: 39891777 PMC: 11787210. DOI: 10.1007/s11011-025-01538-5.

A Network Pharmacology Study and Experimental Validation to Identify the Potential Mechanism of Heparan Sulfate on Alzheimer's Disease-Related Neuroinflammation.

Kim D, Kweon B, Oh J, Lim Y, Noh G, Yu J Biomedicines. 2025; 13(1).

PMID: 39857687 PMC: 11761859. DOI: 10.3390/biomedicines13010103.

Brivaracitam Ameliorates Increased Inflammation, Oxidative Stress, and Acetylcholinesterase Activity in Ischemic Mice.

Deval C, Sharma P, Sharma B, Singh B Clin Psychopharmacol Neurosci. 2025; 23(1):120-132.

PMID: 39820118 PMC: 11747741. DOI: 10.9758/cpn.24.1216.

References

Armstrong R . Risk factors for Alzheimer's disease. Folia Neuropathol. 2019; 57(2):87-105. DOI: 10.5114/fn.2019.85929. View

Dickstein J, Moldofsky H, Lue F, Hay J . Intracerebroventricular injection of TNF-alpha promotes sleep and is recovered in cervical lymph. Am J Physiol. 1999; 276(4):R1018-22. DOI: 10.1152/ajpregu.1999.276.4.R1018. View

Mrak R . Microglia in Alzheimer brain: a neuropathological perspective. Int J Alzheimers Dis. 2012; 2012:165021. PMC: 3359674. DOI: 10.1155/2012/165021. View

Gabbita S, Srivastava M, Eslami P, Johnson M, Kobritz N, Tweedie D . Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflammation. 2012; 9:99. PMC: 3403851. DOI: 10.1186/1742-2094-9-99. View

Xie P . TRAF molecules in cell signaling and in human diseases. J Mol Signal. 2013; 8(1):7. PMC: 3697994. DOI: 10.1186/1750-2187-8-7. View

Galasko D, Montine T . Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med. 2010; 4(1):27-36. PMC: 2850111. DOI: 10.2217/bmm.09.89. View

Gregory A, Dendrou C, Attfield K, Haghikia A, Xifara D, Butter F . TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012; 488(7412):508-511. PMC: 4268493. DOI: 10.1038/nature11307. View

Chen Y, Chen H, Lan J, Chen D . Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis. Joint Bone Spine. 2010; 77(4):366-7. DOI: 10.1016/j.jbspin.2010.01.017. View

Kepp K, Robakis N, Hoilund-Carlsen P, Sensi S, Vissel B . The amyloid cascade hypothesis: an updated critical review. Brain. 2023; 146(10):3969-3990. DOI: 10.1093/brain/awad159. View

10.

Lainez B, Fernandez-Real J, Romero X, Esplugues E, Canete J, Ricart W . Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. Int Immunol. 2003; 16(1):169-77. DOI: 10.1093/intimm/dxh014. View

11.

Rajabi H, Ahmadi M, Aslani S, Saberianpour S, Rahbarghazi R . Exendin-4 as a Versatile Therapeutic Agent for the Amelioration of Diabetic Changes. Adv Pharm Bull. 2022; 12(2):237-247. PMC: 9106955. DOI: 10.34172/apb.2022.025. View

12.

Vitkovic L, Bockaert J, Jacque C . "Inflammatory" cytokines: neuromodulators in normal brain?. J Neurochem. 2000; 74(2):457-71. DOI: 10.1046/j.1471-4159.2000.740457.x. View

13.

Halliday G, Robinson S, Shepherd C, Kril J . Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol. 2000; 27(1-2):1-8. DOI: 10.1046/j.1440-1681.2000.03200.x. View

14.

Liao Y, Wang B, Cheng H, Kuo L, Wolfe M . Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem. 2004; 279(47):49523-32. DOI: 10.1074/jbc.M402034200. View

15.

Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B . TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 1999; 13(1):63-8. DOI: 10.1096/fasebj.13.1.63. View

16.

Culjak M, Perkovic M, Uzun S, Strac D, Erjavec G, Leko M . The Association between TNF-alpha, IL-1 alpha and IL-10 with Alzheimer's Disease. Curr Alzheimer Res. 2020; 17(11):972-984. DOI: 10.2174/1567205017666201130092427. View

17.

Boulanger L . Immune proteins in brain development and synaptic plasticity. Neuron. 2009; 64(1):93-109. DOI: 10.1016/j.neuron.2009.09.001. View

18.

He P, Liu Q, Wu J, Shen Y . Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. FASEB J. 2011; 26(1):334-45. PMC: 3250242. DOI: 10.1096/fj.11-192716. View

19.

Alvarez V, Mata I, Gonzalez P, Lahoz C, Martinez C, Pena J . Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease. Am J Med Genet. 2002; 114(5):574-7. DOI: 10.1002/ajmg.10515. View

20.

Wajant H, Pfizenmaier K, Scheurich P . Tumor necrosis factor signaling. Cell Death Differ. 2003; 10(1):45-65. DOI: 10.1038/sj.cdd.4401189. View